Status: Finalised
First registered on:
06/04/2016
Last updated on:
25/11/2022
1. Study identification
EU PAS Register NumberEUPAS13031
Official titleAlert generation using the case-population approach in the French claims databases
Study title acronymALCAPONE
Study typeObservational study
Brief description of the studyALCAPONE aims to assess the suitability of the French nationwide healthcare insurance system database (SNIIRAM and EGB) for drug safety signal generation based on the OMOP reference set and methodologies, and the case-population approach. Once the initial calibration is completed, methods will be tested on incident alerts and suspected drugs.
Was this study requested by a regulator?No
Is the study required by a Risk Management Plan (RMP)?
Not applicable
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Department/Research grouppharmacoepidemiology
Organisation/affiliationUniversity of Bordeaux
Details of (Primary) lead investigator
Title Professor
Last name Moore
First name Nicholas
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Not applicable (single centre)
Countries in which this study is being conducted
National study
France
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed28/12/201428/12/2014
Start date of data collection02/10/201702/10/2017
Start date of data analysis01/11/2017
Date of interim report, if expected18/08/2017
Date of final study report31/12/201931/10/2019
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companies
Charities
Government bodyDirection Générale de l’Offre de Soins (DGOS)100
Research councils
EU funding scheme
5. Contact details for enquiries
Scientific Enquiries
Title Dr
Last name Thurin
First name Nicolas
Address line 1146 Rue Leo Saignat
Address line 2
Address line 3
CityBordeaux
Postcode33076
CountryFrance
Phone number (incl. country code)33557579209
Alternative phone number33557574675
Fax number (incl. country code)33557574740
Public Enquiries
Title Dr
Last name Thurin
First name Nicolas
Address line 1146 Rue Leo Saignat
Address line 2
Address line 3
CityBordeaux
Postcode33076
CountryFrance
Phone number (incl. country code)33557579209
Alternative phone number33557574675
Fax number (incl. country code)33557574740
6. Study drug(s) information
Not applicable (disease/epidemiology study)
7. Medical conditions to be studied
Medical condition(s)Yes
Acute myocardial infarction
Upper gastrointestinal haemorrhage
Acute kidney injury
Acute hepatic failure
8. Population under study
Age
Term newborns (0-27 days)
Infants and toddlers (28 days - 23 months)
Children (2 - 11 years)
Adolescents (12 - 17 years)
Adults (18 - 44 years)
Adults (45 - 64 years)
Adults (65 - 74 years)
Adults (75 years and over)
Sex
Male
Female
9. Number of subjects
Estimated total number of subjects66000000
Additional information
A preliminary EGB extraction will enable the estimation of the annual number of cases by event of interest, and facilitate the determination of SNIIRAM length of extraction in order to reach enough power. Number of patients per disease entity will depend on population event rates.
10. Source of data
Is this study being carried out with an established data source?Yes
Data sources not registered with ENCePP
SNIIRAM, France
EGB, France
Sources of data
Administrative database, e.g. claims database
SNIIRAM database is the French healthcare insurance system database that contains individual anonymous information on all reimbursed outpatient claims and is linked to the national hospital-discharge summaries database system (PMSI) and the national death registry.
EGB (Echantillon Généraliste des Bénéficiaires) is a permanent 1/97th representative sample of SNIIRAM.
11. Scope of the study
What is the scope of the study?
Risk assessment
Pharmacovigilance signal generation
Primary scope : Pharmacovigilance signal generation
12. Main objective(s)
What is the main objective of the study?
The main objectives are:
(i) To assess the performance of SNIIRAM for the detection of drug safety signals based on the OMOP reference set and methodologies
(ii) To develop on SNIIRAM the case-population approach and assess its performance for safety signal generation based on the OMOP reference set.
Are there primary outcomes?Yes
This study is based on the validation of the database according to the OMOP reference set (several series of molecules that have - positive controls - or have not - negative controls - been associated with four main events of interest).
The identification of the true positive and the true negative drug-event pairs could be considered as the primary outcomes.
Are there secondary outcomes?No
13. Study design
What is the design of the study?
Case-control study
Self controlled case-series
Case-population study
14. Follow-up of patients
Will patients be followed up?Not applicable/no follow-up
15. Data analysis plan
Please provide a brief summary of the analysis method
Three different designs are envisaged:
(i) Case-control design
Odds ratios (OR) will be calculated using a conditional logistic regression. Several degrees of matching will be considered, going from non-matched approach to disease risk score matching including loose matching on simply age and sex.
(ii) Self-controlled case series
Risk periods will be determined based on exposition and presumed biological mechanisms. Relative incidences (RI) for the risk periods will be computed.
(iii) Case-population approach
Case population ratio (CPR) will be calculated according to two distinct exposure approaches: a person-time approach and a per-user approach.
The following evaluation criteria will be used to compare designs performance
The receptor operating characteristics (ROC) will be used to choose the best compromise between sensitivity and specificity among the different designs and their variants according to drug-event pair characteristics.
16. ENCePP seal
Are you requesting the ENCePP seal for this study?
Yes
17. Full protocol
18. Study Results
Please list the 5 most relevant publications using data from your study
ReferenceLink to web-publication
Thurin, NH, Lassalle, R, Schuemie, M, et al. Empirical assessment of case‐based methods for drug safety alert identification in the French National Healthcare System database (SNDS): Methodology of the ALCAPONE project.
Pharmacoepidemiol Drug Saf. 2020 Sep;29(9):993-1000.https://doi.org/10.1002/pds.4983
Thurin, NH, Lassalle, R, Schuemie, M, et al. Empirical assessment of case‐based methods for identification of drugs associated with upper gastrointestinal bleeding in the French National Healthcare System database (SNDS).
Pharmacoepidemiol Drug Saf. 2020 Aug;29(8):890-903.https://doi.org/10.1002/pds.5038
Thurin, NH, Lassalle, R, Schuemie, M, et al. Empirical assessment of case-based methods for identification of drugs associated with acute liver injury in the French National Healthcare System database (SNDS).
Pharmacoepidemiol Drug Saf. 2021 Mar;30(3):320-333.https://doi.org/10.1002/pds.5161
19. Other relevant documents
Other documentsNot
submitted
